AKT1 and prostate carcinoma: For example, studies demonstrated that miR-7-5p inhibited EGFR mRNA and protein expression and downstream AKT and ERK1/2 activity in head and neck [33], breast, lung, and prostate cancers [34], as well as in glioblastoma multiforme [35].